Given the regular appearance of patients who appear unable to tolerate levothyroxine, I thought this paper had the potential to be very interesting. And indeed the abstract is fascinating - as far as it goes. The full paper will be accessible in PubMed Central from 01/06/2020.
Eur Thyroid J, 8 (6), 319-323
Dec 2019
Treatment With Intramuscular Levothyroxine in Refractory Hypothyroidism
María de Los Ángeles Garayalde Gamboa 1 , Melina Saban 1 , Marina Ines Curriá 1
Affiliations
• PMID: 31934558
• PMCID: PMC6944946 (available on 2020-06-01)
• DOI: 10.1159/000503324
Abstract
Introduction: Orally and daily levothyroxine (LT4) is the treatment of choice for hypothyroidism. In the majority of cases, the lack of effectiveness by this way may be due to poor adherence; however, gastrointestinal malabsorption may explain more cases of thyroxine refractoriness than previously reputed, due to the number of occult forms of these disorders.
Case presentation: A 55-year-old white man with a diagnosis of low risk of recurrence of follicular variant of papillary thyroid carcinoma was treated with total thyroidectomy, 30 mCi iodine 131, and oral LT4. A year before he presented a gastric adenocarcinoma that required a partial gastrectomy. He evolved with multiple episodes of intestinal subocclusion that had to be treated with enterectomy in the first instance, then digestive rest and total parenteral nutrition. In spite of having made increases in oral LT4 dose (3 µg/kg), the patient persisted with a thyroid-stimulating hormone level >100 mIU/L. For this reason, we decided to administer intramuscular LT4.
Conclusion: Since there are no guidelines or consensus of intramuscular LT4 use, our experience and how we decided the dose and way of administration are presented in this article to contribute to future cases.
Keywords: Intramuscular levothyroxine; Levothyroxine therapy; Refractory hypothyroidism.
Copyright © 2019 by S. Karger AG, Basel.
Conflict of interest statement
The authors have no conflicts of interest to declare. Química Montpellier Laboratory provides LT4 only for parenteral use because this compound is not for sale for patients in Argentina. The laboratory delivers it to the Buenos Aires British Hospital pharmacy free of charge and given the clinical condition of the patient, without requesting any kind of compensation from the attending physicians.